{
  "id": 21278743,
  "title": "High GPX4 Expression Marks an Oxidative-Metabolic, PD-L1/CD47-Low and Stroma-Poor Tumor State in Hepatocellular Carcinoma",
  "url": "https://urgent.news/2026/11/22/high-gpx4-expression-marks-an-oxidative-metabolic-pd-l1-cd47-low-and",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-22T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.11.13.766360v1?rss=1"
  },
  "original_language": "en",
  "account": "A study has found that increased expression of a protein called Glutathione peroxidase 4 (GPX4) in hepatocellular carcinoma (HCC) tumors is linked to a specific set of immune and metabolic characteristics. The research, which analyzed RNA-sequencing data from 366 primary HCC tumors, discovered that tumors with higher GPX4 expression tend to have lower levels of PD-L1, CD47, CD163, and a fibroblast/extracellular-matrix score. These associations remained significant even after adjusting for factors such as tumor purity, CTNNB1 and TP53 mutations, age, and sex.\n\nThe study further revealed that GPX4-high tumors exhibit enrichment in oxidative phosphorylation, mitochondrial, fatty-acid, xenobiotic, and glutathione metabolism programs, while they lack extracellular-matrix, TGF-beta, and cell-adhesion programs. However, GPX4 expression did not correlate with a T-cell-inflamed profile, CD8 T-cell score, cytolytic activity, or an NRF2 target-gene score. In fact, higher GPX4 expression was associated with lower expression of NFE2L2. Despite the findings, the research indicates that GPX4 expression does not have a prognostic value in HCC patients, as it does not impact overall survival. The study's correlative findings are based on a single cohort and require further external validation and functional testing.",
  "summary": "Background: Glutathione peroxidase 4 (GPX4) protects cancer cells from ferroptosis and is a candidate therapeutic target in hepatocellular carcinoma (HCC). How GPX4 expression relates to the immune and metabolic features of patient tumors is not well characterized. Methods: We analyzed RNA-sequencing data from 366 primary tumors of the TCGA-LIHC PanCancer Atlas cohort (365 with survival data).…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}